Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 231

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 231
---
2022. In addition to base salary and bonus, the Contract of Employment provided for additional benefits, such as a 10%
pension contribution, medical insurance, vacation benefits and any other additional benefits as determined by the Board of Directors from
time to time.

Dr. Zamoryakhin also agreed
that, for a period of six months following his termination (as reduced by any “garden leave” period), he would not compete
with the Company, directly or indirectly, or solicit any customer, prospective customer or key employee. The Contract of Employment
included provisions related to confidentiality and the non-disclosure of information and assignment of inventions. Among other
things, these provisions prohibit Dr. Zamoryakhin from disclosing any of our proprietary and confidential information received during
the course of employment and require Dr. Zamoryakhin to assign to us any inventions conceived or developed during the course of his employment.

The Contract of Employment
provided that we will pay Dr. Zamoryakhin his normal salary during any notice period prior to termination. We are also permitted
to terminate Dr. Zamoryakhin’s employment effective immediately, without notice or payment, if Dr. Zamoryakhin is found guilty of
any fundamental or repudiatory breach of contract or any breach of the disciplinary rules applicable to Dr. Zamoryakhin.

On July 4, 2024, Dr. Zamoryakhin
departed the Company. In connection with his departure, Dr. Zamoryakhin and the Company entered into a settlement agreement, pursuant
to which, among other things, Dr. Zamoryakhin received (i) £107,000, in lieu of his notice entitlement period, and (ii) a termination
payment of £30,000. Any option awards that had not vested as of the date of departure were forfeited.

Board of Directors

Our Board of Directors is
currently comprised of five directors, one of whom is an executive director and four of whom are non-executive directors, reflecting a
blend of different experience and backgrounds. The roles of Chairman of the Board of Directors (which is a non-executive position) and
Chief Executive Officer have been split and there is a clear division of responsibility between the two positions. With a view towards
maintaining the independence of the Board of Directors, no remuneration is paid to either the Chairman or non-executive directors in the
form of shares.

Effective as of September
28, 2018, all AIM quoted companies were